Why Mexican children with Alagille lag behind in getting proper care
Children in Mexico living with the complex genetic disease Alagille syndrome have limited access to essential care, including confirmatory genetic testing at diagnosis and,…
News
Hepatitis D therapy RBD1016 wins orphan drug designation in EU
The European Medicines Agency (EMA) has granted orphan drug designation to Suzhou Ribo Life Science’s experimental therapy RBD1016 for hepatitis D. The EMA gives…
This year, it’s ‘hope into action’ for PSC Awareness Day
Oct. 29 is Global PSC Awareness Day, and advocates around the world are joining forces to shine a light on primary sclerosing cholangitis (PSC)…
2 simple nutrients may be effective new screening tool for ICP
A new study has identified two dietary nutrients, choline and dimethylglycine, as effective potential biomarkers for diagnosing and monitoring intrahepatic cholestasis of pregnancy (ICP).
Long-term ketogenic diet may cause fatty liver disease, per mouse study
A long-term ketogenic diet, which favors fats over carbs, may promote weight loss, but it can also cause fatty liver disease and blood sugar…
Potential biliary atresia treatment AX-0810 to enter clinical testing
AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing cholangitis (PSC), is about to…
Autoimmune hepatitis therapy hits FDA roadblock, future uncertain
Kezar Life Sciences has hit a roadblock in plans to develop zetomipzomib, its experimental treatment for autoimmune hepatitis (AIH). The company has…
Seladelpar approved in Canada as Lyvdelzi to treat adults with PBC
Health Canada has conditionally approved Gilead Sciences’ seladelpar — to be marketed in the country under the brand name Lyvdelzi — as a second-line…
Itching was main sign of teen’s liver disease: Case report
Itching was the main symptom leading to the diagnosis of progressive familial intrahepatic cholestasis (PFIC) type 3 in a teenage boy in Portugal, a…
New Helix dataset aims to accelerate liver disease research
A new dataset from genomics company Helix aims to accelerate research into metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease.
Recent Posts
- A boys’ day out brings a welcome sense of normalcy
- Rezdiffra reduces liver scarring in high-risk MASH patients: Trial data
- Used in Alagille mice, ASO therapy found to improve liver function
- Gene-editing therapy PBGENE-HBV shows encouraging trial results
- Livdelzi maintains benefits for up to 3 years in PBC: Phase 3 data